Document is current

Article History

Received: 18 June 2024

Accepted: 23 August 2024

First Online: 14 December 2024

Declarations

:

: Focke Ziemssen: Travel grants and personal fees: Allergan/AbbVie, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Clearside, Janssen, Novartis, Novo Nordisk, Merck, Sharp & Dohme, Regeneron, Roche/Genentech, Sanofi, Sandoz, and Stada. Michelle Sylvanowicz: Employee: Bayer; Winfried M. Amoaku: Advisory board membership: AbbVie, Alcon, Alimera, Allergan, Apellis, Bayer, Bausch + Lomb, Bioeq, Novartis, and Pfizer; Speaker fees: Alimera, Allergan, Bayer, Novartis, and Pfizer; Support for travel: Alimera, Allergan, Bayer, Novartis, and Pfizer; Research sponsorship and funding: Allergan, Bayer, Boehringer Ingelheim, CenterVue, Gyroscope, Novartis, and Optos; Tariq Aslam: Tariq Aslam is an Editor in Chief of <i>Ophthalmology and Therapy</i>, and was not involved in the selection of peer reviewers for the manuscript nor any subsequent editorial decisions. Consultant: Bausch & Lomb, Bayer, Laboratoires Théa Pharmaceuticals, Novartis, Oraya, and Roche; Bora Eldem: Consultant: Allergan, Bayer, Novartis, and Roche; Robert P. Finger: Research grant: CentreVue, Heidelberg Engineering, Novartis, and Zeiss; Consultant: Alimera, Allergan, Bayer, Ellex, Inositec, Novartis, Opthea, Roche/Genentech, and Santhera; Support for travel: Novartis; Richard P. Gale: Consultant/advisory boards: Allergan, Alimera, Bayer, Novartis, and Santen; Educational travel grants: Allergan, Bayer, Heidelberg, and Novartis; Research grants: Allergan, Bayer, Novartis, and Roche; Laurent Kodjikian: Consultant: AbbVie, Alcon, Allergan, Bayer, Krystal Biotech, Novartis, Regeneron, and Théa; Jean-François Korobelnik: Consultant: AbbVie, Apellis, Bayer, Eyepoint Pharma, Ocuphire, Roche, Thea, Carl Zeiss Meditec; Member of DSMB for Alexion, Novo Nordisk, Opthea; Xiaofeng Lin: Consultant: Bayer; Anat Loewenstein: Consultant: 4DMT, AbbVie, Alkeus, Annexon, Apellis, Astellas, Bayer Health Care, Beyeonics, Eyepoint, Johnson & Johnson, NotalVision, Novartis, Ocular Therapeutics, Oculis, Ocuphire Pharma, Ocuterra, Opthea, Oxurion, Roche, Syneos; Paul Mitchell: Consultant: Allergan, Bayer, and Novartis; Steering Committee member: Bayer; Moira Murphy: Employee: Exploristics, Ltd.; David R. Owens: Consultant: Bayer; Nick Parker: Employee: The International Agency for the Prevention of Blindness; Ian Pearce: Lecture fees: Allergan, Bayer, Heidelberg Pharma, and Novartis; Consultant: Allergan, Alimera, Bayer, and Novartis, Support for travel: Allergan, Bayer, and Novartis; Francisco J. Rodríguez: Consultant: Bayer, Novartis, and Roche; Speaker: Bayer, Novartis, and Roche; Research funding: Novartis; Jude Stern: Employee: The International Agency for the Prevention of Blindness; S. James Talks: Advisory board member, speaker fees, and research support: Bayer and Novartis; Research grants: Boehringer Ingelheim and Roche; Consultant: Bayer; David T. Wong: Grants/research support: Bayer, Novartis, and Roche; Consultant: Alcon, Allergan, Apellis, Bausch Health, Bayer, Novartis, Roche, Topcon, and Zeiss; Equity: Arctic DX; Tien Yin Wong: Consulting fees/travel support/review fees: Aldropika Therapeutics, Bayer, Boehringer Ingelheim, Genentech, Iveric Bio, Novartis, Oxurion, Plano, Roche, Sanofi, Shanghai Henlius; Stock: EyRIS; Jane Barratt: Consultant: Bayer.

: The survey was developed according to guidelines from the Declaration of Helsinki and the World Health Organization’s International Ethical Guidelines for Biomedical Research. As a Primary Market Research Survey, ethics committee approvals are not required; however, local requirements were assessed by individual institutions and countries. Informed consent was acquired, no personally identifiable information was collected, and the survey did not inform treatment decisions.